| Dolutegravir | Bictegravir | Cabotegravir | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SPRING-2a | SINGLE | GEMINI-1 and -2b – Pooled Analysis | GS-US-380–1489a | GS-US-380–1490a | FLAIR and ATLAS – Pooled Analysis | ||||||||
Adverse reaction | DTG n = 411 | RAL n = 411 | DTG n = 414 | EFV n = 419 | DTG/3TC n = 716 | DTG and FTC/ TDF n = 717 | DTG n = 315 | BIC n = 314 | DTG n = 325 | BIC n = 320 | CAB n = 591 | CAR n = 591 | |
Diarrhea | 11% | 11% | 17% | 18% | 9% | 11% | 13% | 13% | 12% | 12% | – | – | |
Nausea | 14% | 13% | 14% | 14% | 4% | 7% | 23% | 10% | 9% | 8% | 3% | 1% | |
Vomiting | – | – | 5% | 5% | – | – | 5% | 4% | – | – | – | – | |
Fatigue | 5% | 4% | 13% | 12% | - | - | 9% | 6% | 8% | 6% | 5% |  < 1% | |
Upper respiratory infection | 6% | 6% | 9% | 10% | 8% | 6% | 11% | 6% | 7% | 5% | – | – | |
Dizziness | 6% | 6% | 9% | 35% | – | – | – | – | 1% | 2% | 2% |  < 1% | |
Headache | 12% | 12% | 13% | 13% | 10% | 10% | 14% | 11% | 12% | 13% | 4% |  < 1% | |
Insomnia | 5% | 4% | 15% | 10% | 4% | 6% | 6% | 4% | 4% | 5% | – | – | |
Depression | 5% | 3% | 6% | 6% | – | – | – | – | – | – | - | – | |
Rash | – | – | 3% | 14% | – | – | – | – | – | – | 2% | 0% | |
Pyrexia | – | - | - | - | - | - | – | – | – | – | 8% | 0% | |
Injection site reactions | – | – | – | – | – | - | – | – | - | – | 83% | 0% | |
Discontinuations due to drug-related clinical adverse events | 2% | 2% | 2% | 10% | 1% | 1% | 1% | 0% |  < 1% | 2% | 80% | – | |
References | [92] | [93] | [96] | [97] | [98] |